推荐产品
方案
≥98% (HPLC)
表单
powder
颜色
faint brown-red to dark red
溶解性
DMSO: 0.5 mg/mL, clear
储存温度
2-8°C
SMILES字符串
N(c3cc4c(cncc4)cc3)C1=CC(=O)C(=O)c2c1cccc2
InChI key
NYDMVPHEEBVAHT-UHFFFAOYSA-N
生化/生理作用
Hsp90 inhibitor with anti-cancer efficacy in vitro and in vivo.
YZ129 is an ATP site-targeting Hsp90 inhibitor (IC50 = 29.5 nM against 2.5 nM geldanamycin-FITC for binding human HSP90α) that prevents thapsigargin (1 μM)-induced NFAT nuclear translocation in HeLa cells (IC50 = 820 nM) by blocking HSP90 client calcineurin-mediated NFAT dephosphorylation. YZ129 (5 μM; 24-48 hr) suppresses U87 glioblastoma (GBM) cell migration and proliferation as a result of G2/M arrest and apoptosis induction. Daily intraperitoneal administration is efficacious against U87 xenografts (s.c.; bilateral posterior limbs)-derived tumor growth in mice in vivo.
其他说明
Product may exist in a Tautomeric Form.
储存分类代码
13 - Non Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
Zhenzhen Liu et al.
Cell chemical biology, 26(3), 352-365 (2019-01-15)
Glioblastoma (GBM) is among the most common and malignant types of primary brain tumors in adults, with a dismal prognosis. Although alkylating agents such as temozolomide are widely applied as the first-line treatment for GBM, they often cause chemoresistance and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门